WithHealth Publishes Whitepaper on Strengthening Workplace Safety
What employers must do, can do, and should do to protect their workforce and their customers from COVID-19SAN DIEGO, CA...
Year: 2022
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
FT. MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing...
Syneos Health Releases 2022 Dealmakers’ Intentions Survey
As Industry Dynamics Shift, Smaller Biotechnology Companies Will Continue to Drive Dealmaking in 2022MORRISVILLE, N.C., Jan. 11, 2022 (GLOBE NEWSWIRE) --...
Parexel Bolsters Regulatory and Access Offering with Key Appointment
Former Health Advances Partner Wyatt Gotbetter appointed Head of Parexel Worldwide Access Consulting to drive growth in consulting businessBOSTON, and...
Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company
-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed- -REVTx-99 was tested prior to infection in multiple...
T2 Biosystems Announces the Initiation of the T2Resistance® Panel Clinical Trial
LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing...
Resonant Recognized as One of the Three Leading BAW Filter Innovators Since the Start of 2020
Company’s Intellectual Property Portfolio Expands to over 415 Filed or Issued Patents; 265 of Which are Focused on XBAR® (BAW)...
Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
SOLANA BEACH, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the United Kingdom’s Home...
Biomea Fusion Announces Participation at the H.C. Wainwright 2022 BioConnect Conference
REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated...
Positive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug Therapy
American Journal of Nephrology data demonstrates KidneyIntelX successfully monitors patient response to SGLT2 therapy in 1,325 CANagliflozin CardioVAScular Assessment Study...
Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones
Enrollment complete in INTERGRIS-IPF Phase 2a clinical trial with top-line data expected mid-2022 FDA has authorized evaluation of long-term treatment...
AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2...
Eko Chief Medical Officer, Dr. Adam Saltman, Accepted into Forbes Technology Council
Forbes Technology Council, Invitation-Only Community for World-Class Technology Executives, Welcomes Dr. Saltman of Eko Eko Chief Medical Officer Dr. Adam...
Yumanity’s Approach to Neurodegenerative Diseases Validated by Two External Collaborations
Yumanity achieves research milestone in its collaboration with Merck; Yumanity to receive $5 million milestone payment Michael J. Fox Foundation...
iCAD Announces the Appointment of New Members to its Board of Directors
Dana Brown and Timothy Norris Irish offer extensive experience in technology, women’s breast health and unique global perspectivesNASHUA, N.H., Jan....
Reflect Scientific Inc., Message from the President
OREM, Utah, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services...
CV Sciences, Inc. Announces Launch of +PlusCBD™ Pain Relief Topicals
+PlusCBD™ expands product offerings to include four new topicals that provide targeted pain relief +PlusCBD™ Pain Relief topicals +PlusCBD™ Pain...
Aramis Biosciences Announces FDA Clearance of IND Application for A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Disease
Aramis Biosciences plans to initiate a Phase II clinical trial in Q1 2022BOSTON, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aramis...
Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer
PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery...
H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.
Targets one of Healthcare’s Largest Multi-Billion Dollar Markets: Cardiac ElectrophysiologyTAMPA, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB:...